Statins may act through increasing tissue plasminogen activator/plasmin activity to lower risk of Alzheimer's disease.
Tsai
Shih-Jen
SJ
Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.
D000544:Alzheimer Disease / Q000378:metabolism* / Q000517:prevention & control*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000818:Animals; D001057:Apolipoproteins E / Q000378:metabolism; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D010446:Peptide Fragments / Q000378:metabolism; D011498:Protein Precursors / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000378:metabolism*
D016229:Amyloid beta-Peptides; D001057:Apolipoproteins E; D019208:Brain-Derived Neurotrophic Factor; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010446:Peptide Fragments; D011498:Protein Precursors; C538897:amyloid beta-protein (40-42); C426674:brain-derived neurotrophic factor precursor; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin